A Study of Erlotinib (Tarceva) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Roche

Most Recent Events

18 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
23 May 2013 Planned End Date changed from 1 Dec 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
19 Feb 2013 Planned end date changed from 1 Jan 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight